Year None202420232022202120202019 Oct 24, 2024 Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Ato Oct 23, 2024 Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Confe Oct 18, 2024 Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Derm Oct 04, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 25, 2024 New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatiti Sep 24, 2024 FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatm Sep 19, 2024 Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTE Sep 05, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 05, 2024 Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last » Displaying 1 - 9 of 50